AntibodyTargeted-Drug Conjugates 2015

13-15 April 2015, Crowne Plaza Porto, Porto, Portugal

  • Increase font size
  • Default font size
  • Decrease font size

Day One

Final Conference Programme | Monday 13th April 2015

08.30-09.25
Registration

09.25-09.30
Welcome & Opening Remarks
John A Flygare (Genentech Inc, South San Francisco, California, USA)

SESSION 1:
PLENARY SESSION

Moderator: John A Flygare (Genentech Inc, South San Francisco, California, USA)

09.30-10.00
KEYNOTE:
‘ADCs using the maytansinoid platform: After Kadcyla, whats next?’

John Lambert (ImmunoGen Inc, Waltham, Massachusetts, USA)

10.00-10.30
KEYNOTE:
‘Next generation ADCs: Expanding the ADC target space by enabling ADCs against tumors with low target expression’

Peter Park (Mersana Therapeutics Inc, Cambridge, Massachusetts, USA)

10.30-11.00
Coffee Break & Poster Set-Up

SESSION 2:
PLENARY II

Moderator: Hans-Peter Gerber (Pfizer Worldwide R&D, Pearl River, New York, USA)

11.00-11.30
‘The development of antibody pyrrolobenzodiazepine conjugates’
Philip Howard (Spirogen Ltd, London, UK)

11.30-12.00
‘Novel ADC targets/ADC target discovery’
David Tice (Medimmune Inc., Gaitherburg, Maryland, USA)

12.00-12.30
‘The next generation of antibody conjugates: Moving beyond cytotoxic payloads’
Greg Bleck (Catalent Pharma Solutions, Madison, Wisconsin, USA)

12.30-13.00
‘Potent and selective a-Amanitin-antibody conjugates’
Kendall Morrison (Agensys Inc., Santa Monica, California, USA)

13.00-14.00
Lunch Break & Posters

SESSION 3:
CONJUGATION TECHNOLOGIES

Moderator: Aaron Sato (Sutro Biopharma Inc., South San Francisco, California, USA)

14.00-14.30
KEYNOTE:
‘Antibody-drug conjugates: An emerging modality for the targeted therapy of liquid and solid tumors’

Hans-Peter Gerber (Pfizer Worldwide R&D, Pearl River, New York, USA)

14.30-15.00
‘Sortase-mediated generation of site-specifically conjugated next-generation ADCs for treatment of cancer’
Roger R. Beerli, Nikolas Stefan, Tamara Hell, Anna S. Merkel and Ulf Grawunder (NBE-Therapeutics Ltd, Basel, Switzerland)

15.00-15.30
‘Distinct in vivo efficacy and PK outcomes of ADCs conjugated site specifically using SMARTag™ technology’
David Rabuka (Catalent Pharma Solutions, Catalent Biologics - West (formerly Redwood Bioscience, Emeryville, California USA)

15.30-16.00
‘Beyond CMO services: New conjugation technologies’
Laurent Ducry (Lonza AG, Visp, Switzerland)

16.00-16.30
Tea Break & Posters

SESSION 4:
ALTERNATIVE STRATEGIES

Moderator: John Lambert (ImmunoGen Inc, Waltham, Massachusetts, USA)

16.30-17.00
‘Induction of avidity driven hyper-clustering of DR5 by a novel tetravalent bispecific FAP--DR5 antibody (RG7386) leads to strong anti-tumor efficacy’
Klaus Bosslet (Roche Diagnostics GmbH, Penzberg, Germany)

17.00-17.30
‘Antibody conjugated nanoparticles – an alternative ADC platform’
Christopher Scott (Queen’s University Belfast, Belfast, Northern Ireland, UK)

17.30-18.00
‘A hybrid antibody-nanocarrier conjugate to expose tumors to “Sentinels” of immunity’
Pirouz Daftarian (University of Miami, Miami, Florida, USA)

18.00-18.20
‘New tools for developability assessments of ADCs’
Maria Wendt (Genedata AG, Basel, Switzerland)

 

ATDC 2015 Sponsors

  • Catalent
  • NBE Therapeutics
  • LinXis
  • ImmunoGen
  • DNAvaccine.com
  • ONdrugDelivery
  • Sutro Biopharma
  • Nascent Biologics
  • Pfizer Oncology
  • Synthon
  • ADC Review
  • Biovest
  • Genentech
  • Aldevron
  • Oncozine
  • NatureGeneTherapy.com

ATDC 2015 Downloads

ATDC 2015 Leaflet

ATDC 2015 Mailing List

Name
E-mail Address
What is 3+2-1?